GNPX

Genprex, Inc.

2.11 USD
+0.20 (+10.47%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Genprex, Inc. stock is up 2.93% since 30 days ago. The next earnings date is Aug 19, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 July’s closed higher than June.

About Genprex, Inc.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.